220 related articles for article (PubMed ID: 30451040)
1. Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.
Kalla R; Boyapati R; Vatn S; Hijos G; Crooks B; Moore GT; Hall V; Lipscomb G; Gomollón F; Jahnsen J; Singh S
Scand J Gastroenterol; 2018 Dec; 53(12):1437-1442. PubMed ID: 30451040
[TBL] [Abstract][Full Text] [Related]
2. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.
Motaganahalli S; Beswick L; Con D; van Langenberg DR
Intern Med J; 2019 Jan; 49(1):94-100. PubMed ID: 29962008
[TBL] [Abstract][Full Text] [Related]
3. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
Conroy S; Hale MF; Cross SS; Swallow K; Sidhu RH; Sargur R; Lobo AJ
J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
5. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.
Elnawsra O; Fok I; Sparrow M; Gibson P; Andrews J; Connor S
Intern Med J; 2016 May; 46(5):590-5. PubMed ID: 26946938
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
Amcoff K; Stridsberg M; Lampinen M; Magnuson A; Carlson M; Halfvarson J
Scand J Gastroenterol; 2017 Mar; 52(3):344-350. PubMed ID: 27881032
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
Kennedy NA; Clark A; Walkden A; Chang JC; Fascí-Spurio F; Muscat M; Gordon BW; Kingstone K; Satsangi J; Arnott ID; Lees CW
J Crohns Colitis; 2015 Jan; 9(1):41-9. PubMed ID: 25135754
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
9. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
11. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
12. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
13. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.
Mowat C; Digby J; Strachan JA; Wilson R; Carey FA; Fraser CG; Steele RJ
Gut; 2016 Sep; 65(9):1463-9. PubMed ID: 26294695
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
15. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
Högberg C; Karling P; Rutegård J; Lilja M
Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders.
Lozoya Angulo ME; de Las Heras Gómez I; Martinez Villanueva M; Noguera Velasco JA; Avilés Plaza F
Gastroenterol Hepatol; 2017 Mar; 40(3):125-131. PubMed ID: 27260632
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
[TBL] [Abstract][Full Text] [Related]
19. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
[TBL] [Abstract][Full Text] [Related]
20. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
